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Acute lymphoblastic leukemia in
childhood is the domain of chemotherapy giving
rates of event free survival of up to 80% for the
vast majority of children. Only 6% of well defined
high risk patients during frontline treatment but
on the other side the majority of children
following relapse do not have a satisfying
chance of cure by chemotherapy alone. The
controversy persists, whether hematopoietic
stem cell transplants provide a superior chance
of cure. The answer can only be given by clearly
defined prospective studies including patients
with the intention to transplant but finally events
before the transplant can be performed. The
BMF group is currently conducting such a study
during frontline therapy. Out of 3050 children
with newly diagnosed ALL 197 patients fulfilled
the criteria for a matched related bone marrow
transplantation. An acceptable family donor was
available in 53 children, which is in the expected
range of 27% of HLA-identical siblings or family
members in Germany. Only 30 children have
been transplanted at the end, using a
conditioning regimen of fractionated TBI (6 x 2
Gy) and VP16 (60mg/kg). Although the
transplanted children have an EFS of about
70% and the whole group with a donor and the
intention to transplant of about 60% compared
to 30% EFS in the complementary group, the
transplant group is by far too small lead to
furtherincrease of survival in the whole group of
children with ALL. Some children received
alternative conditioning regimens with obviously
less chance of cure. But the major question for
41
the future remains the donor availability for high
risk frontline patients but more important for
relapse patients in order to prove the transplant
approach in general in such patients. Clearly
autografts seem not to give any advantage in
these type of children, unless any new
approach of maintenance/immunotherapy is
providing a significant additional effect.
Unrelated grafts on the other side might be one
option but still require a significant reduction of
treatment risks, which are currently still in the
range of 30-50% compared to 10% and less in
matched related transplants. Cord blood
transplants especially in children may be
superior to adult marrow or peripheral blood
stem cell transplants. And finally, first steps
have been done now to overcome the high
rejection rate of mismatched related grafts by
increasing for example the stem cell dose and
thus offering another source of stem cell grafts
also for ALL patients. Unfortunately, also these
transplants are still associated with high
transplant related risks. Almost all centers
employing haploidentical stem cell transplants
are using TBI containing regimens even with an
increased dose. Our own approach on this fields
is to understand the side effects of conditioning
regimens containing TBI on the homing process
of stem cells in the microenvironment of the
marrow, and to overcome ex vivo as well as in
vivo such critical dysfunctions with the aim to
ensure engraftment and limit transplant risks by
accelerating the hematopoietic and lymphopoietic
reconstitution. This model will be discussed.
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